Merck ends Phase 2 trial of Alzheimer’s drug MK-1167 from partner Neuphoria
read at Endpoints ↗Negative
Merck announced it has terminated a mid-stage Phase 2 study of an experimental Alzheimer’s therapy.
The drug, called MK-1167, is an oral candidate that was being developed in collaboration with biotech Neuphoria.
The decision ends the partnership's current trial effort, but Merck did not provide details on the reasons or next steps.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Merck scraps a Phase 2 Alzheimer's asset from partner Neuphoria”
read at Endpoints ↗77 words · retrieved Jul 1
comments(0)
5-min edit window · permanent after that